how drug companies mislead doctors and harm patients /
First Statement of Responsibility
Ben Goldacre
EDITION STATEMENT
Edition Statement
1st American ed
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
New York :
Name of Publisher, Distributor, etc.
Faber and Faber,
Date of Publication, Distribution, etc.
2013
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
xvii, 426 p. :
Other Physical Details
ill. ;
Dimensions
22 cm
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index
CONTENTS NOTE
Text of Note
Missing data -- Where do new drugs come from? -- Bad regulators -- Bad trials -- Bigger, simpler trials -- Marketing -- Better data
0
SUMMARY OR ABSTRACT
Text of Note
In this book the author puts the $600 billion dollar global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess. His previous book Bad Science exposed the tricks that quacks and journalists use to distort science. In this follow-up, he points out that doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply buried. All of this is perfectly legal. In fact, even government regulators withhold vitally important data from the people who need it most. Doctors and patient groups have stood by too, and failed to protect us. Instead, they take money and favours, in a world so fractured that medics and nurses are now educated by the drugs industry. Patients are harmed in huge numbers. The author, a writer on the science behind medicine, here shows exactly how the science has been distorted, how our systems have been broken, and what is needed to fix them
TOPICAL NAME USED AS SUBJECT
Clinical trials-- Moral and ethical aspects
Drugs-- Quality control
Drugs-- Testing
Drugs-- Testing-- Moral and ethical aspects
Pharmaceutical industry-- Moral and ethical aspects